GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).
The sale of anti-rabies treatment Rabipur and Encepur, used for the
prevention of tick-borne encephalitis, by the British drugmaker includes
milestone payments of up to 495 million euros.
https://www.marketscreener.com/BAVARIAN-NORDIC-A-S-1412846/news/GSK-to-sell-two-travel-vaccines-to-Danish-biotech-firm-29421835/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.